Economic implications of novel regimens for tuberculosis treatment in three high-burden countries: a modelling analysis
The Lancet Global Health
June 2024 /open access/
-- Accompanying comment: Economic aspects of shortening the duration of tuberculosis treatment
/open access/
**************
Bedaquiline-pretomanid-moxifloxacin-pyrazinamide for drug-sensitive and drug-resistant pulmonary tuberculosis treatment: a phase 2c, open-label, multicentre, partially randomised controlled trial
The Lancet Infectious Diseases
17 May 2024 /open access/
**************
Relationship between HIV viral suppression and multidrug-resistant tuberculosis treatment outcomes
PLOS Global Public Health
6 May 2024 /open access/
**************